Navigation Links
Alimera Sciences Closes $30 Million in Series C Financing, Increasing Stake in Medidur(TM) FA
Date:3/18/2008

ATLANTA, March 18 /PRNewswire/ -- Alimera Sciences today announced that it has closed a Series C financing round of $30 million with all five of the company's existing venture capital firms exercising the right to participate at their full pro rata share.

The proceeds from the Series C will enable Alimera to, as previously announced, acquire a majority stake in Medidur(TM) FA, the company's Phase III investigative treatment for diabetic macular edema (DME), from development partner pSivida Ltd (Nasdaq: PSDV, ASX: PSD, Xetra: PSI) and fund the remaining development obligations for the product.

Under the new agreement, Alimera will assume pSivida's Medidur FA development responsibilities and increase its share of future profits from 50 to 80 percent. For this increased equity in Medidur FA, Alimera has paid pSivida $12 million in cash and has issued a $15 million note (which would accrue interest of up to $6 million over the life of the note) and will make an additional $25 million milestone payment upon FDA approval of the product. Alimera Sciences will also assume pSivida's remaining development obligations.

"Alimera is fortunate to have received continued support from our investors who share our confidence in the potential Medidur FA can bring to the many sufferers of DME," said Dan Myers, President and CEO of Alimera Sciences.

In connection with this acquisition, Alimera will complete the licensing of the Medidur technology for use with NADPH oxidase inhibitors recently obtained from Emory University. Alimera is pursuing a treatment for dry AMD with these compounds.

"Alimera will now also have solidified access to the Medidur delivery platform for our announced NADPH oxidase inhibitors for the treatmen
'/>"/>

SOURCE Alimera Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Alimera Sciences Signs Second Agreement With Emory University for Potential Treatments Using New Class of Antioxidants
2. Edwards Lifesciences to Present at the Citi 5th Annual Small and Mid-Cap Conference
3. Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update
4. Edwards Lifesciences to Present at the Cowen and Company Annual Healthcare Conference
5. Pressure BioSciences, Inc. Announces Move to New Corporate Offices
6. Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences
7. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming SAWC Conference
8. Numira Biosciences Names New Board Member
9. DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board
10. Annual meeting of the National Academy of Sciences
11. Advanced Life Sciences to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 -- Only about half of all pregnant ... leaving thousands of moms-to-be and their babies at increased risk ... should be a routine part of prenatal care," said Edward ... providers should offer their pregnant patients a flu shot each ... it." , A report by the U.S. Centers for Disease ...
(Date:9/18/2014)... German . In ... fight a pathogen tooth and nail, but rather tolerate it to ... of tolerance is that the disease only progresses very slowly ... pathogen load. , Roland Regoes, a senior scientist at ETH Zurich,s ... He set about investigating whether there are infected people who are ...
(Date:9/18/2014)... CRDF Global released today its ... edition – rich with videos, images and interactive ... Global empowers scientists and innovators around the world. ... foundation and individual supporters, CRDF Global reaches across ... training and entrepreneurship. , The Annual Report highlights ...
(Date:9/18/2014)... Africa (PRWEB) September 18, 2014 Phela ... adopt the HABIT™ Program in South Africa. ... Health and Wellness, and distributed in South Africa by ... the HABIT program, which has been tailored to address ... HABIT™ focuses on behavior modification and chronic disease prevention. ...
(Date:9/18/2014)... new expert panel report, Improving Medicines for Children ... Canadian Academies, addresses the importance of developing safe ... half of Canada,s seven million children use at ... is done off-label (i.e. the prescription differs from ... have historically been excluded in drug research and ...
Breaking Medicine News(10 mins):Health News:Flu vaccine for expectant moms a top priority 2Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:CRDF Global Launches Media-Rich Digital Edition of Annual Report, Tells Story of Empowering Scientists and Innovators around the World in 2013 2Health News:Improving medicines for children in Canada 2
... Event at Penn State Hershey to Launch 2008 ... Thousands of,Pennsylvania taxpayers who participate in the ... Research deserve recognition for the,thousands of dollars in ... year. On Monday, February 11 at 9:30 a.m., ...
... Montreal, 6 February 2008 - A recent study by ... Health Centre research Institute, sheds some new light on ... Hastons study is pointing at genetics as contributing to ... implications in changing therapeutic practices. The article was published ...
... ) announced today that its Chief Executive Officer, Mark,McAndrew, and Chief Financial Officer, ... Conference in,New York City. Torchmark,s presentation is scheduled to begin at 2:20 p.m.,EST., ... The presentation will be webcast live at:, ... http://www.torchmarkcorp.com ...
... Group on,Health (NBGH) and the Office of Minority Health ... 2008 at 1:30 p.m. EST to announce a new,initiative ... improve the quality of health care for a culturally ... and public health,together to develop guidance and strategies for ...
... Tobacco-Free Kids, WASHINGTON, Feb. 7 The World ... clear both,the devastating scope of the global tobacco epidemic ... the world today - and the fact that it ... presents the first comprehensive picture of what the world,s ...
... February 19, 9 a.m. - 5 p.m.), SCOTTSDALE, ... Children,s Dental Health Month. Dr. Lee Weinstein, a ... Associates for Kids Only, will be offering a Free ... a.m. until 5 p.m., The first 30 patients that ...
Cached Medicine News:Health News:The Pennsylvania Breast Cancer Coalition Announces 2008 Breast Cancer Income Tax Check-Off Grant Recipients 2Health News:Landmark WHO Report on Global Tobacco Epidemic Should Spur Urgent Action by Nations to Implement Proven Solutions 2Health News:Landmark WHO Report on Global Tobacco Epidemic Should Spur Urgent Action by Nations to Implement Proven Solutions 3Health News:Free Children's Dental Day; Expert Source on Children's Dental Health Available 2
(Date:9/18/2014)... ARBOR, Mich. , Sept. 18, 2014  A ... Research will allow the University of Michigan to establish ... The Glenn Center for Aging Research at ... evidence that drugs can slow the effects of aging ... unlock mechanisms of aging that can help develop medications ...
(Date:9/18/2014)... SAN DIEGO , Sept. 18, 2014 /PRNewswire/ ... today announced that the U.S. Food and Drug ... patient enrollment and dosing of PEGPH20 in SWOG,s ... is designed to evaluate Halozyme,s investigational drug PEGPH20 ... FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic ...
(Date:9/18/2014)... -- Australian biomarker discovery company Minomic International Ltd will ... prostate cancer screening test, planning to achieve US Food ... Minomic,s proprietary MiStat™ technology is a screening assay ... known as the MIL-38 antigen. This biomarker is present ... Researchers at 11 leading urology centres in ...
Breaking Medicine Technology:$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2
... , ALLEGAN, Mich. , Jan. 19 ... release financial results for its second quarter fiscal 2010 on Tuesday, ... Company will conduct a conference call at 10:00 a.m. (ET) ... Officer. , The conference call will be available live via webcast to ...
... LAKE CITY , Jan. 19 World Heart ... circulatory systems, announced today that the first U.S. implant of ... INTEGRIS Baptist Medical Center ("INTEGRIS") in Oklahoma City ... the first implant in the Levacor VAD bridge-to-transplant ("BTT") study, ...
Cached Medicine Technology:Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010 2WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City 2WorldHeart Announces First U.S. Implant of Levacor(TM) VAD Implant at INTEGRIS in Oklahoma City 3
Straight shafts with 0.5 mm teeth and 6 mm tying platform. Wide serrated handle with thumb catch lock and polished finish....
Straight shafts with 0.12 mm teeth and tying platform. Serrated handle with polished finish....
Heavy curved shafts with 2 x 2 teeth and crisscross serrated 6 mm tying platform. Serrated handle with polished finish....
Straight shafts with 5.5 mm tying platform. 0.3 mm gap at platform heel. True round knurled handle in the closed position. Polished finish. Tips: 0.12 mm teeth....
Medicine Products: